Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill (Preserving Patient Access to Long-Term Care Pharmacies Act) creates a temporary mandatory per‑prescription "supply fee" that Medicare Part D prescription drug plans (PDP sponsors) and Medicare Advantage prescription drug plans (MA–PD organizations) must pay long‑term care (LTC) pharmacies for certain Part D drugs dispensed to beneficiaries in 2026 and 2027. The fee is set at $30 per specified prescription in 2026 and is indexed for 2027 by the annual percentage increase defined in current law.
Role of federal intervention: liberal and centrist view targeted federal action as justified to preserve access; conservative objects to mandated payments and increased federal spending.
Relative to its intended legislative type, this bill is a focused statutory amendment that clearly mandates temporary supply‑fee payments to long‑term care pharmacies, provides for repayment subsidies from the Secretary, creates a civil‑money‑penalty enforcement tool, and requires a GAO study.
The bill (Preserving Patient Access to Long-Term Care Pharmacies Act) creates a temporary mandatory per‑prescription "supply fee" that Medicare Part D prescription drug plans (PDP sponsors) and Medicare Advantage prescription drug plans (MA–PD organizations) must pay long‑term care (LTC) pharmacies for certain Part D drugs dispensed to beneficiaries in 2026 and 2027.
The fee is set at $30 per specified prescription in 2026 and is indexed for 2027 by the annual percentage increase defined in current law.
The bill requires the fee to be paid in addition to other pharmacy reimbursements, imposes a civil money penalty (minimum $10,000) on plans that fail to pay, and directs the Secretary to reimburse plan sponsors/MA organizations for the aggregate amount of fees paid (a subsidy) within 18 months after each plan year.
Content-wise the bill is a targeted, time-limited intervention intended to preserve access to a specific provider type, which increases tractability. Its explicit federal backfill reduces opposition from plans but increases federal cost, creating opposition from fiscal hawks. The presence of enforcement penalties and administrative interactions with Part D add some friction. Taken together, these features place it in the middle range of likelihood: more likely than sweeping or highly ideological reforms, but not among the easiest technical fixes to pass without further legislative packaging or negotiation.
Relative to its intended legislative type, this bill is a focused statutory amendment that clearly mandates temporary supply‑fee payments to long‑term care pharmacies, provides for repayment subsidies from the Secretary, creates a civil‑money‑penalty enforcement tool, and requires a GAO study. It is well integrated into existing statutory provisions and precise about key substantive elements (who pays, who receives, what amount, when).
Role of federal intervention: liberal and centrist view targeted federal action as justified to preserve access; conservative objects to mandated payments and increased federal spending.
These are examples from the analysis, not a ranked list of the most-affected groups.
Role of federal intervention: liberal and centrist view targeted federal action as justified to preserve access; conservative objects to mandated payments and increased federal spending.
A mainstream liberal would likely view the bill largely positively as a targeted, short‑term intervention to shore up access to long‑term care pharmacy services for vulnerable Medicare beneficiaries.
They would see the mandated supply fee and the explicit prohibition on offsetting other pharmacy reimbursements as a protection for LTC pharmacies that serve nursing homes and similar settings.
They would welcome the GAO study requirement to guide longer‑term policy changes, but may see the two‑year period as only a stopgap and want a permanent, more comprehensive solution.
A centrist/ pragmatic observer would consider the bill a narrowly targeted, temporary policy designed to address a specific access problem for a vulnerable population.
They would appreciate the short‑term nature and the requirement for a GAO study to inform longer‑term policy, but would be attentive to potential fiscal effects, administrative complexity, and unintended consequences.
They would look for clarity about the scope of affected prescriptions and the expected fiscal cost and would prefer implementation details that limit disturbance to plan operations and beneficiaries.
A mainstream conservative would likely be skeptical of the bill because it mandates payments by private plan sponsors and then uses federal funds to reimburse those sponsors, creating a top‑down requirement and new federal spending.
They would question whether the market failure alleged is proven, whether government intervention is the right tool, and whether this creates precedent for further federal micromanagement of plan‑pharmacy pricing.
They might be open to limited, evidence‑based remedies if the GAO study shows a genuine access crisis, but would prefer market‑based or state‑level solutions and stronger fiscal restraints.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise the bill is a targeted, time-limited intervention intended to preserve access to a specific provider type, which increases tractability. Its explicit federal backfill reduces opposition from plans but increases federal cost, creating opposition from fiscal hawks. The presence of enforcement penalties and administrative interactions with Part D add some friction. Taken together, these features place it in the middle range of likelihood: more likely than sweeping or highly ideological reforms, but not among the easiest technical fixes to pass without further legislative packaging or negotiation.
The bill has not accumulated any surfaced votes yet.
Role of federal intervention: liberal and centrist view targeted federal action as justified to preserve access; conservative objects to ma…
Content-wise the bill is a targeted, time-limited intervention intended to preserve access to a specific provider type, which increases tra…
Relative to its intended legislative type, this bill is a focused statutory amendment that clearly mandates temporary supply‑fee payments to long‑term care pharmacies, provides for repayment subsidies from the Secretary…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.